Corient Capital Partners’s BioMarin Pharmaceuticals BMRN Stock Holding History

Corient Capital Partners’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	$259K	Hold	3,126	–	–	0.02%	512
2022 Q2	$259K	Buy	3,126 +530	+20%	+$42.2K	0.02%	529
2022 Q1	$200K	Sell	2,596 -106	-4%	-$8.87K	0.01%	686
2021 Q4	$239K	Sell	2,702 -123	-4%	-$10.1K	0.02%	601
2021 Q3	$218K	Buy	2,825 +212	+8%	+$16.7K	0.02%	610
2021 Q2	$218K	Buy	+2,613	New	+$207K	0.02%	599
2021 Q1	–	Sell	-2,292	Closed	-$201K	–	619
2020 Q4	$201K	Buy	+2,292	New	+$182K	0.02%	481
2020 Q3	–	Sell	-9,955	Closed	-$1.23M	–	511
2020 Q2	$1.23M	Buy	9,955 +1,899	+24%	+$189K	0.15%	131
2020 Q1	$680K	Buy	+8,056	New	+$694K	0.11%	165

Other funds holding BMRN

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Corient Capital Partners's BMRN Position: Q3 2022 in Review

Corient Capital Partners held its BioMarin Pharmaceuticals (BMRN) position steady in Q3 2022 at 3,126 shares worth $259K. The position accounts for 0.02% of the portfolio, ranked #512.

Corient Capital Partners first reported a position in BMRN in Q1 2020 and has held it in 9 quarters since. The position peaked at $1.23M in Q2 2020. 551 funds tracked by Wall St. Rank hold BMRN as of Q3 2022.

Corient Capital Partners held 3,126 shares of BioMarin Pharmaceuticals worth $259K as of Q3 2022.
Corient Capital Partners left its BioMarin Pharmaceuticals share count unchanged in Q3 2022.
BioMarin Pharmaceuticals made up 0.02% of Corient Capital Partners's portfolio in Q3 2022, its #512 holding.
Corient Capital Partners first reported a position in BioMarin Pharmaceuticals in Q1 2020 and has held it in 9 quarters since.
Corient Capital Partners's BioMarin Pharmaceuticals position peaked at $1.23M in Q2 2020.
551 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q3 2022.

Based on Corient Capital Partners's 13F filing for Q3 2022, filed 14 Nov 2022.